您好,欢迎您

2026 ESMO SRC丨肉瘤Oral摘要汇总

03月18日
整理:肿瘤资讯
来源:ESMO官网

2026年欧洲肿瘤内科学会(ESMO)肉瘤与罕见肿瘤大会(Sarcoma and Rare Cancers)于3月12日至14日在瑞士卢加诺举行。在大会首日的“Mini Oral session 1: Sarcoma”专场中,多项重磅研究结果公布,涵盖了从患者生活质量评估、肉瘤亚型预后分析到泛欧洲罕见肿瘤分子谱分析等多个维度。本期肿瘤资讯特别整理了该专场的核心口头报告摘要,以飨读者。

Mini Oral session 1: Sarcoma

摘要号:78MO
Title:
A health-related quality of life measurement strategy for solid rare cancers: Primary findings from the EORTC quality of life group (QLG) QoL rare cancer study.
标题:实体罕见肿瘤健康相关生活质量测量策略:EORTC生活质量组(QLG)罕见肿瘤生活质量研究的初步发现
讲者:Catarina S. Padilla(Amsterdam, Netherlands)

摘要号:79MO
Title:
Five subtypes of undifferentiated sarcomas: Presentation and outcome of 7545 patients from the NETSARC+ registry.
标题:五种亚型未分化肉瘤:来自NETSARC+研究登记7545例患者的表现与临床结局
讲者:Jean-Yves Blay(Lyon, France)

摘要号:80MO
Title:
Evaluation of clinicopathological features and prognoses of patients with brain sarcoma.
标题:脑肉瘤患者临床病理特征及预后评估
讲者:Halis Yerlikaya(Ankara, Türkiye)

摘要号:81MO
Title:
Final analysis of the pan-European Arcagen study for molecular profiling and access to treatment for rare cancers: A joint EORTC-EURACAN initiative.
标题:泛欧洲Arcagen研究的最终分析:罕见肿瘤的分子谱分析与治疗可及性(一项EORTC-EURACAN联合倡议)
讲者:Marie Morfouace(Villejuif, France)

摘要号:82MO
Title:
Pooled analysis of two prospective trials on reduced dose preoperative radiotherapy in primary myxoid liposarcoma - correlation of pathologic responses and treatment outcomes.
标题:原发性黏液样脂肪肉瘤术前减量放疗两项前瞻性试验的汇总分析——病理缓解与治疗结局的相关性
讲者:Hanna M. Kosela Paterczyk(Warsaw, Poland)

摘要号:83MO
Title:
Pembrolizumab after adriamycin-based chemotherapy in patients with soft-tissue sarcoma: A real-world comparative analysis of second-line efficacy.
标题:帕博利珠单抗在软组织肉瘤患者接受基于阿霉素化疗后的应用:二线疗效的真实世界比较分析
讲者:Jesus Rodriguez Pascual(Madrid, Spain)

摘要号:84MO
Title:
Phase I study of the tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) combined with irinotecan (I) and temozolomide (T) in adolescents and adults with Ewing sarcoma.
标题:四价死亡受体5(DR5)激动剂ozekibart(INBRX-109)联合伊立替康(I)和替莫唑胺(T)在青少年及成人尤文肉瘤患者中的I期研究
讲者:Ana Sebio Garcia(Barcelona, Spain)

摘要号:85MO
Title:
Cabozantinib as maintenance therapy in high grade uterine sarcoma after stabilization or response to doxorubicin +/- ifosfamide regimen: Results from EORTC 62113-55115-STBSG-GCG (NCT01979393), randomized double-blind phase II study.
标题:卡博替尼作为高级别子宫肉瘤患者在接受多柔比星+/-异环磷酰胺方案后病情稳定或缓解的维持治疗:EORTC 62113-55115-STBSG-GCG(NCT01979393)随机双盲II期研究结果
讲者:Isabelle L. Ray-Coquard(Lyon, France)

摘要号:86MO
Title:
Anti-HHV-8 immunity defines dostarlimab efficacy in HIV-associated Kaposi’s sarcoma: Results of the STARKAP trial.
标题:抗HHV-8免疫决定了多塔利单抗(dostarlimab)在HIV相关卡波西肉瘤中的疗效:STARKAP试验结果
讲者:Claudia A. Fulgenzi(London, United Kingdom)


责任编辑:肿瘤资讯-古木
排版编辑:肿瘤资讯-古木
版权声明
本文专供医学专业人士参考,未经著作人许可,不可出版发行。同时,欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明"转自:良医汇-肿瘤医生APP"。